Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares

Benjamin Hohl, CFO of Enliven Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 27, 2025, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised stock options to acquire 3,250 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 3,250 shares of common stock at a weighted average price of $21.5932, with individual sales ranging from $21.14 to $22.135.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 13,000 shares of common stock and holds options for 147,056 shares.
• The options vest over time, with the initial vesting occurring on August 2, 2022, and the remaining shares vesting in 36 equal monthly installments.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance of the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a key executive, but the pre-planned nature of the transactions mitigates potential concerns.

Key Dates